Advarra Offers Complimentary Transfer of IRB Oversight

Advarra is providing free resources to support and enable the clinical research during the coronavirus disease (COVID-19) pandemic. This includes complimentary transfer of IRB oversight, access to a new version of Forte eRegulatory management software, eReg Lite, and a dedicated "Ask Advarra" resource for guidance on emerging issues impacted by COVID-19.

"Advarra has been reviewing more COVID-19 research since the beginning with priority reviews and reduced fees, but we wanted to do more," said Robann Cunningham, Chief Commercial Officer at Advarra. "COVID-19 has not adversely impacted Advarra's business thanks to our virtual capabilities, and we feel it is our responsibility to give back since we have the expertise, depth of resources, and technology to keep research moving forward during these challenging times."


Currently imposed restrictions may limit the ability of local IRBs to appropriately oversee ongoing research. To help prevent these local IRB challenges from leading to unnecessary study closures, Advarra is offering free transfer of IRB oversight through the end of 2020. The Advarra IRB will review the transferred studies and sites and continue as the IRB of record until the local IRB is prepared to re-take the studies.


To help streamline remote workflows for researchers and enable remote access to sponsors and CROs, Advarra is offering its research technology customers a free version of Forte eReg software—eReg Lite—for the remainder of 2020. eReg Lite provides features that enable virtual telework and collaboration such as remote monitoring capabilities, electronic signatures, and delegation of authority. The software integrates with the OnCore Enterprise Research System.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.